Hepatic encephalopathy – recent advances in treatment and diagnosis

References

• European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J Hepatol. 2022;77(3):807–824.
   PubMedGoogle Scholar
• Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–735.
   PubMed Web of Science ®Google Scholar
• Romero-Gomez M, Boza F, Garcia-Valdecasas MS, et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001;96:2718–2723.
   PubMed Web of Science ®Google Scholar
• Riggio O, Nardelli S, Moscucci F, et al. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Clin Liver Dis. 2012;16(1):133–146.
   PubMed Web of Science ®Google Scholar
• Ridola L, Cardinale V, Riggio O. The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies. Ann Gastroenterol. 2018;31:151–164.
   PubMed Web of Science ®Google Scholar
• Di Pascoli M, Ceranto E, Nardi PD, et al. Hospitalizations due to cirrhosis: clinical aspects in a large cohort of Italian patients and cost analysis report. Dig Dis. 2017;35:433–438.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Riggio O, Allampati S, et al. Cognitive dysfunction is associated with poor socioeconomic status in patients with cirrhosis: an international multicenter study. Clin Gastroenterol Hepatol. 2013;11(11):1511–1516.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Schubert CM, Heuman DM, et al. Persistence of cognitive impairment after resolution of overt hepatic encephalopathy. Gastroenterology. 2010;138(7):2332–2340.
   PubMed Web of Science ®Google Scholar
• Nardelli S, Allampati S, Riggio O, et al. Hepatic encephalopathy is associated with persistent learning impairments despite adequate medical treatment: a multicenter, international study. Dig Dis Sci. 2017;62(3):794–800.
   PubMed Web of Science ®Google Scholar
• Labenz C, Baron JS, Toenges G, et al. Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients. Aliment Pharmacol Ther. 2018;48:313–321.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Boparai N, Price LL, et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol. 2001;96:2199–2205.
   PubMed Web of Science ®Google Scholar
• Nardelli S, Gioia S, Ridola L, et al. Risk of falls in patients with cirrhosis evaluated by timed up and go test: does muscle or brain matter more? Dig Liver Dis. 2022;54(3):371–377.
   PubMedGoogle Scholar
• Bajaj JS, Hafeezullah M, Hoffmann RG, et al. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol. 2007;102:1903–1909.
   PubMed Web of Science ®Google Scholar
• Levitt DG, Levitt MD. A model of blood-ammonia homeostasis based on a quantitative analysis of nitrogen metabolism in 436 the multiple organs involved in the production, catabolism, and excretion of ammonia in humans. Clin Exp Gastroenterol. 2018;437(11):193–215.
   Google Scholar
• Elwir S, Rahimi RS. Hepatic encephalopathy: an update on the pathophysiology and therapeutic options. J Clin Transl Hepatol. 2017;5:1–10.
   PubMedGoogle Scholar
• Wright G, Noiret L, Olde Damink SW, et al. Interorgan ammonia metabolism in liver failure: the basis of current and future therapies. Liver Int. 2011;31:163–175.
   PubMed Web of Science ®Google Scholar
• Shawcross DL, Sharifi Y, Canavan JB, et al. Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol. 2011;54:640–649.
   PubMed Web of Science ®Google Scholar
• Dhiman RK. Gut microbiota, inflammation and hepatic encephalopathy: a puzzle with a solution in sight. J Clin Exp Hepatol. 2012;2:207–210.
   PubMedGoogle Scholar
• Gupta A, Dhiman RK, Kumari S, et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol. 2010;53:849–855.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Ridlon JM, Hylemon PB, et al. Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J PhysiolGastrointest Liver Physiol. 2012;302(1):G168–75.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Hylemon PB, Ridlon JM, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to 454 cognition and inflammation. Am J Physiol Gastrointest Liver Physiol. 2012;303((6)):G675–85.
   PubMed Web of Science ®Google Scholar
• Montano-Loza AJ, Angulo P, Meza-Junco J, et al. Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis. J Cachexia Sarcopenia Muscle. 2016;7:126–135.
   PubMed Web of Science ®Google Scholar
• Eslamparast T, Montano-Loza AJ, Raman M, et al. Sarcopenic obesity in cirrhosis—the confluence of 2 prognostic titans. Liver Int. 2018;38:1706–1717.
   PubMed Web of Science ®Google Scholar
• Bhanji RA, Moctezuma-Velazquez C, Duarte-Rojo A, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis. Hepatol Int. 2018;12:377–386.
   PubMed Web of Science ®Google Scholar
• Gallagher D, Kuznia P, Heshka S, et al. Adipose tissue in muscle: a novel depot similar in size to visceral adipose tissue. Am J Clin Nutr. 2005;81:903–910.
   PubMed Web of Science ®Google Scholar
• Dasarathy S, Mookerjee RP, Rackayova V, et al. Ammonia toxicity: from head to toe? Metab Brain Dis. 2017;32:529–538.
   PubMed Web of Science ®Google Scholar
• Dasarathy SJ. Myostatin and beyond in cirrhosis: all roads lead to sarcopenia. J Cachexia Sarcopenia Muscle. 2017;8:864–869.
   PubMed Web of Science ®Google Scholar
• Gioia S, Ridola L, Cristofaro L, et al. The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Liver Int. 2021;41(12):2965–2973.
   PubMed Web of Science ®Google Scholar
• Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol. 2015;62(2):437–447.
   PubMed Web of Science ®Google Scholar
• Riggio O, Efrati C, Catalano C, et al. High prevalence of spontaneous portosystemic shunts in persistent hepatic encephalopathy: a case-control study. Hepatology. 2005;42:1158–1165.
   PubMed Web of Science ®Google Scholar
• Simon-Talero M, Roccarina D, Martinez J, et al. Association between portosystemic shunts and increased complications and mortality in patients with cirrhosis. Gastroenterology. 2018;154:1694–1705.
   PubMed Web of Science ®Google Scholar
• Montagnese S, Russo FP, Amodio P, et al. Hepatic encephalopathy 2018: a clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis. 2019;51:190–205.
   PubMedGoogle Scholar
• Amodio P. Hepatic encephalopathy: diagnosis and management. Liver Int. 2018;38(6):966–975.
   PubMed Web of Science ®Google Scholar
• Nardelli S, Ridola L, Gioia S, et al. Management of hepatic encephalopathy not responsive to first-line treatments. Curr Treat Options Gastroenterol. 2018;16:253–259.
   PubMedGoogle Scholar
• Weissenborn K. Hepatic encephalopathy: definition, clinical grading and diagnostic principles. Drugs. 2019;79(Suppl 1):5–9.
   PubMedGoogle Scholar
• Nardone R, Taylor AC, Höller Y, et al. Minimal hepatic encephalopathy: a review. Neurosci Res. 2016;111:1–12.
   PubMed Web of Science ®Google Scholar
• Kircheis G, Wettstein M, Timmermann L, et al. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology. 2002;35:357–366.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Thacker LR, Heuman DM, et al. The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology. 2013;58(3):1122–1132.
   PubMed Web of Science ®Google Scholar
• Amodio P, Ridola L, Schiff S, et al. Improving the inhibitory control task to detect minimal hepatic encephalopathy. Gastroenterology. 2010;139:510–518.
   PubMed Web of Science ®Google Scholar
• Luo M, Ma P, Li L, et al. Advances in psychometric tests for screening minimal hepatic encephalopathy: from paper-and-pencil to computer-aided assessment. Turk J Gastroenterol. 2019;30:398–407.
   PubMed Web of Science ®Google Scholar
• Campagna F, Montagnese S, Ridola L, et al. The animal naming test: an easy tool for the assessment of hepatic encephalopathy. Hepatology. 2017;66:198–208.
   PubMed Web of Science ®Google Scholar
• Pantham G, Mullen KD. Practical issues in the management of overt hepatic encephalopathy. Gastroenterol Hepatol. 2017;13(11):659–665.
   Google Scholar
• Merli M, Lucidi C, Pentassuglio I, et al. Increased risk of cognitive impairment in cirrhotic patients with bacterial infections. J Hepatol. 2013;59:243–250.
   PubMed Web of Science ®Google Scholar
• Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10(2):166–173.
   PubMed Web of Science ®Google Scholar
• Kim G, Kang SH, Kim MY, et al. Prognostic value of sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis. PLoS One. 2017;12:e0186990.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70:172–193.
   PubMed Web of Science ®Google Scholar
• Hanai T, Shiraki M, Nishimura K, et al. Sarcopenia impairs prognosis of patients with liver cirrhosis. Nutrition. 2015;31:193–199.
   PubMed Web of Science ®Google Scholar
• Nardelli S, Lattanzi B, Merli M, et al. Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis. Hepatology. 2019;70(5):1704–1713.
   PubMed Web of Science ®Google Scholar
• Merli M, Giusto M, Lucidi C, et al. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. Metab Brain Dis. 2013;28:281–284.
   PubMed Web of Science ®Google Scholar
• Nardelli S, Lattanzi B, Torrisi S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement. Clin Gastroenterol Hepatol. 2017;15:934–936.
   PubMed Web of Science ®Google Scholar
• Lattanzi B, D’Ambrosio D, Manuela Merli. Sarcopenia: two faces of the same metabolic alteration. J Clin Exp Hepatol. 2019;9:125–130.
   PubMed Web of Science ®Google Scholar
• Kalaitzakis E, Olsson R, Henfridsson P, et al. Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis. Liver Int. 2007;27(9):1194–1201.
   PubMed Web of Science ®Google Scholar
• Meza-Junco J, Montano-Loza AJ, Baracos VE, et al. Sarcopenia as a Prognostic Index of Nutritional Status in Concurrent Cirrhosis and Hepatocellular carcinoma. J Clin Gastroenterol. 2013;47(10):861–870.
   PubMed Web of Science ®Google Scholar
• Praktiknjo M, Simón-Talero M, Römer J, et al. Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. J Hepatol. 2020;72(6):1140–1150.
   PubMed Web of Science ®Google Scholar
• Nardelli S, Riggio O, Turco L, et al. Relevance of spontaneous portosystemic shunts detected with CT in patients with cirrhosis. Radiology. 2021;299(1):133–140.
   PubMed Web of Science ®Google Scholar
• Sharma P, Agrawal A, Sharma BC, et al. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol. 2011;26(6):996–1003.
   PubMed Web of Science ®Google Scholar
• Tromm A, Griga T, Greving I, et al. Orthograde whole gut irrigation with mannite versus paromomycine + lactulose as pro-phylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial. Hepato-gastroenterology. 2000;47(32):473–477.
   PubMedGoogle Scholar
• Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–1081.
   PubMed Web of Science ®Google Scholar
• Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005;42(5):674–679.
   PubMed Web of Science ®Google Scholar
• Bureau C, Thabut D, Jezequel C, et al. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial. Ann Intern Med. 2021;174(5):633–640.
   PubMed Web of Science ®Google Scholar
• Miraglia R, Maruzzelli L, Di Piazza A, et al. Transjugular intrahepatic portosystemic shunt using the new gore viatorr controlled expansion endoprosthesis: prospective, single-center, preliminary experience. Cardiovasc Intervent Radiol. 2019;42(1):78–86.
   PubMed Web of Science ®Google Scholar
• Riggio O, Ridola L, Angeloni S, et al. Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial. J Hepatol. 2010;53(2):267–272.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial. Hepatology. 2017;66:1727–1738.
   PubMed Web of Science ®Google Scholar
• Nardelli S, Gioia S, Ridola L, et al. Radiological intervention for shunt related encephalopathy. J Clin Exp Hepatol. 2018;8(4):452–459.
   PubMed Web of Science ®Google Scholar
• Laleman W, Simon-Talero M, Maleux G, et al. Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology. 2013;57(6):2448–2457.
   PubMed Web of Science ®Google Scholar
• Lv Y, Chen H, Luo B, et al. Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: a randomized controlled trial. Hepatology. 2022;76(3):676–688.
   PubMed Web of Science ®Google Scholar
• Sharma BC, Singh J, Srivastava S, et al. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy. J Gastroenterol Hepatol. 2017;32:1234–1239.
   PubMed Web of Science ®Google Scholar
• Sharma BC, Sharma P, Lunia MK, et al. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol. 2013;108:1458–1463.
   PubMed Web of Science ®Google Scholar
• Rahimi RS, Singal AG, Cuthbert JA, et al. Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial. JAMA Intern Med. 2014;174:1727–1733.
   PubMed Web of Science ®Google Scholar
• Sidhu SS, Sharma BC, Goyal O, et al. L-ornithine L-aspartate in bouts of overt hepatic encephalopathy. Hepatology. 2018;67(2):700–710.
   PubMed Web of Science ®Google Scholar
• Shehata HH, Elfert AA, Abdin AA, et al. Randomized controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2018;30(12):1476–1481.
   PubMed Web of Science ®Google Scholar
• Sharma BC, Sharma P, Agrawal A, et al. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137:885–891.
   PubMed Web of Science ®Google Scholar
• Les I, Doval E, García-Martínez R, et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol. 2011;106:1081–1088.
   PubMed Web of Science ®Google Scholar
• Agrawal A, Sharma BC, Sharma P, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012;107:1043–1050.
   PubMed Web of Science ®Google Scholar
• Dhiman RK, Rana B, Agrawal S, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology. 2014;147:1327–1337.
   PubMed Web of Science ®Google Scholar
• Rockey DC, Vierling JM, Mantry P, et al. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014;59:1073–1083.
   PubMed Web of Science ®Google Scholar
• Varakanahalli S, Sharma BC, Srivastava S, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo. Eur J Gastroenterol Hepatol. 2018;30(8):951–958.
   PubMed Web of Science ®Google Scholar
• Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol. 2016;64:69–78.
   PubMed Web of Science ®Google Scholar
• Hassanein TI, Tofteng F, Brown JRS, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007;46:1853–1862.
   PubMed Web of Science ®Google Scholar
• Bañares R, Nevens F, Larsen FS, et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology. 2013;57:1153–1162.
   PubMed Web of Science ®Google Scholar
• Ridola L, Nardelli S, Gioia S, et al. How to Design a multicenter clinical trial in hepatic encephalopathy. J Clin Exp Hepatol. 2019;9(1):137–145.
   PubMed Web of Science ®Google Scholar
• Dalal R, McGee RG, Riordan SM, et al. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2:CD008716
   PubMed Web of Science ®Google Scholar
• Riggio O, Mannaioni G, Ridola L, et al. Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: a study on the pathophysiology of hepatic encephalopathy. Am J Gastroenterol. 2010;105:1374–1381.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Salzman NH, Acharya C, et al. Faecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial. Hepatology. 2019;70:1690–1703.
   PubMed Web of Science ®Google Scholar
• Mehta R, Kabrawala M, Nandwani S, et al. Preliminary experience with single fecal microbiota transplant for treatment of recurrent overt hepatic encephalopathy-A case series. Indian J Gastroenterol. 2018;37:559–562.
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Fagan A, Gavis EA, et al. Longterm outcomes of fecal microbiota transplantation in patients with cirrhosis. Gastroenterology. 2019;156:1921–1923.
   PubMedGoogle Scholar
• de Cena JA, Zhang J, Deng D, et al. Low-abundant microorganisms: the human microbiome’s dark matter, a scoping review. Front Cell Infect Microbiol. 2021;11:689197.
   PubMed Web of Science ®Google Scholar
• Fagan A, Gavis EA, Gallagher ML, et al. A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study. J Hepatol. 2022 Sep 22;78(2):312–321.
   PubMedGoogle Scholar
• Nardelli S, Gioia S, Faccioli J, et al. Albumin for cognitive impairment after TIPS: a road to be explored. J Hepatol. 2023 Mar;78(3):e96–e97.
   PubMedGoogle Scholar